Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
The effect of TCV-309, a newly developed platelet activating factor (PAF) antagonist, on the wet/dry weight ratio of the lung (index of pulmonary edema) and the pulmonary surface activity (index of pulmonary compliance) was evaluated in comparison with that of CV-3988 (PAF-antagonist). Administration of TCV-309 (1 mg/kg) or CV-3988 (10 mg/kg) significantly reduced the wet/dry weight ratio which was increased by endotoxin administration (3 mg/kg). It also augmented the pulmonary surface activity. Administration of either TCV-309 or CV-3988 alleviated the histologic lesions caused by endotoxic shock. These results suggest that lung injury during endotoxic shock can be controlled by TCV-309 as by CV-3988.
Okano
S
S
Division of Veterinary Surgery, Nippon Veterinary and Animal Science University, Tokyo, Japan.
Tagawa
M
M
Urakawa
N
N
D000818:Animals; D004285:Dogs; D004926:Escherichia coli; D007546:Isoquinolines / Q000494:pharmacology*; D008070:Lipopolysaccharides; D008168:Lung / Q000187:drug effects / Q000473:pathology*; D010742:Phospholipid Ethers / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011654:Pulmonary Edema / Q000473:pathology / Q000503:physiopathology*; D011663:Pulmonary Surfactants / Q000502:physiology*; D011726:Pyridinium Compounds / Q000494:pharmacology*; D012772:Shock, Septic / Q000473:pathology / Q000503:physiopathology*; D044005:Tetrahydroisoquinolines
D007546:Isoquinolines; D008070:Lipopolysaccharides; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D011663:Pulmonary Surfactants; D011726:Pyridinium Compounds; D044005:Tetrahydroisoquinolines; C037913:CV 3988; C067430:TCV 309